OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
USD 4.76
arrow_upward
+0.53%(+0.025) 1H
12 Okt, 2:59:53 PTG GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk OPHLY...
Buka
USD 4.72
Tinggi
USD 4.79
Rendah
USD 4.72
Permodalan Pasaran
1.13T
Purata volum
59.78K
Volum
62.80K
tgi 52 mgu
USD 5.75
rdh 52 mgu
USD 3.81
Beta
0.21
Syer tertunggak
1.50B
Bilangan pekerja
4K
Buka
USD 4.72
Tinggi
USD 4.79
Rendah
USD 4.72
Permodalan Pasaran
1.13T
Purata volum
59.78K
Volum
62.80K
tgi 52 mgu
USD 5.75
rdh 52 mgu
USD 3.81
Beta
0.21
Syer tertunggak
1.50B
Bilangan pekerja
4K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Simply Wall Street
·
3 hari lalu
How Biohaven Licensing Deal At Ono Pharmaceutical Stock Has Changed Its Investment Story
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Perihal Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Pekerja4.21K
Diasaskan1717
Ibu pejabatOsaka, Wilayah Osaka, Jepun
Sektor-
Laman webono-pharma.com